Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed [...]

Intellipharmaceutics hires Doll to commercialize drugs

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has retained Doll Consulting and its principal, David Doll, to assist the company with the commercialization of products in its controlled-release generic drug and NDA portfolios. “We now have four products filed with the FDA for the purpose of obtaining regulatory approval in the U.S. – ANDA’s for Focalin XR, Effexor [...]

FDA accepts Intellipharmaceutics ANDA for generic Protonix

The FDA has accepted Intellipharmaceutics International’s (Nasdaq:IPCI; TSX:I) abbreviated new drug application for a generic version of Protonix, a delayed release pantoprazole sodium,which inhibits gastric acid secretion. The drug is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological [...]

Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]

Intellipharmaceutics files ANDA for generic Protonix

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has filed an ANDA with the FDA for a generic of Protonix (delayed-release pantoprazole sodium), which inhibits gastric acid secretion and is prescribed for conditions such as stomach ulcers associated with gastroesophageal reflux disease and hypersecretory conditions including Zollinger-Ellison syndrome. Sales of pantoprazole sodium delayed-release tablets in the U.S. were about [...]